Abstract 397: Combinatorial use of VHL and KEAP1-based PROTACs reveals unexpected synergy and hook effect relief

Abstract Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules bridging a target protein with an E3 ubiquitin ligase, promoting its ubiquitylation and degradation. Unlike traditional inhibitors, PROTACs exploit transient interactions, enabling the selective degradation of “undruggable” proteins, thereby expanding the landscape of druggable targets. However, PROTACs are not without limitations. The “hook effect”—a phenomenon where high PROTAC concentrations reduce efficacy due to inactive binary complex formation—compromises their clinical utility. Additionally, single PROTACs may fail to achieve complete degradation due to insufficient polyubiquitination or suboptimal E3 ligase recruitment, limiting their therapeutic efficacy. These challenges highlight the need for strategies to enhance PROTAC performance and so therapeutic applicability. In this study, we introduce a novel dual-PROTAC strategy that recruits two distinct E3 ligases, such as KEAP1 and VHL, to cooperatively degrade KRAS(G12D) and Androgen Receptor (AR). Our data demonstrate that combining KEAP1- and VHL-recruiting PROTACs synergistically enhances target degradation, reduces the required dosing, and minimizes off-target effects. Notably, KEAP1 recruitment offers the unique advantage to favour polyubiquitin chains elongation, thereby improving proteasomal recognition. In conclusion, dual-targeting approach represents a promising avenue for optimizing PROTAC-based therapeutics. Citation Format: Sehbanul Islam, Haihong Jin, Dong Liu, Dan Lu, Yunkai Zhang, Renxu Chang, Joel Austin, Thomas Beer, Hsin-Yao Tang, Lan Huang, James Tonra, Luca Busino. Combinatorial use of VHL and KEAP1-based PROTACs reveals unexpected synergy and hook effect relief [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 397.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2025-04-21
DOI
https://doi.org/10.1158/1538-7445.am2025-397
Citations
2
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
1.61
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 397: Combinatorial use of VHL and KEAP1-based PROTACs reveals unexpected synergy and hook effect relief

Sehbanul Islam, Haihong Jin, Yunkai Zhang, Luca Busino et al.
2 citations
Cancer Research
Protein Degradation and Inhibitors
1.61
article

Abstract 397: Combinatorial use of VHL and KEAP1-based PROTACs reveals unexpected synergy and hook effect relief

Sehbanul Islam, Haihong Jin, Yunkai Zhang, Luca Busino, Hsin‐Yao Tang, Dan Lü, James R. Tonra, Joel Austin, Lan Huang, Renxu Chang, Thomas Beer, Dong Liu
article en
2 citations

Abstract

Abstract Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules bridging a target protein with an E3 ubiquitin ligase, promoting its ubiquitylation and degradation. Unlike traditional inhibitors, PROTACs exploit transient interactions, enabling the selective degradation of “undruggable” proteins, thereby expanding the landscape of druggable targets. However, PROTACs are not without limitations. The “hook effect”—a phenomenon where high PROTAC concentrations reduce efficacy due to inactive binary complex formation—compromises their clinical utility. Additionally, single PROTACs may fail to achieve complete degradation due to insufficient polyubiquitination or suboptimal E3 ligase recruitment, limiting their therapeutic efficacy. These challenges highlight the need for strategies to enhance PROTAC performance and so therapeutic applicability. In this study, we introduce a novel dual-PROTAC strategy that recruits two distinct E3 ligases, such as KEAP1 and VHL, to cooperatively degrade KRAS(G12D) and Androgen Receptor (AR). Our data demonstrate that combining KEAP1- and VHL-recruiting PROTACs synergistically enhances target degradation, reduces the required dosing, and minimizes off-target effects. Notably, KEAP1 recruitment offers the unique advantage to favour polyubiquitin chains elongation, thereby improving proteasomal recognition. In conclusion, dual-targeting approach represents a promising avenue for optimizing PROTAC-based therapeutics. Citation Format: Sehbanul Islam, Haihong Jin, Dong Liu, Dan Lu, Yunkai Zhang, Renxu Chang, Joel Austin, Thomas Beer, Hsin-Yao Tang, Lan Huang, James Tonra, Luca Busino. Combinatorial use of VHL and KEAP1-based PROTACs reveals unexpected synergy and hook effect relief [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 397.

Cancer ResearchVol. 85(8_Supplement_1)
The Wistar Institute (US), University of Pennsylvania (US)
Openalex Percentile: Top 18%
Protein Degradation and Inhibitors
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.